stoxline Quote Chart Rank Option Currency Glossary
  
Revvity, Inc. (RVTY)
103.49  -5.01 (-4.62%)    04-12 16:00
Open: 107.46
High: 108.03
Volume: 973,064
  
Pre. Close: 108.5
Low: 103.34
Market Cap: 12,784(M)
Technical analysis
2024-04-12 4:51:59 PM
Short term     
Mid term     
Targets 6-month :  125.03 1-year :  129.43
Resists First :  107.05 Second :  110.81
Pivot price 104.59
Supports First :  100.95 Second :  83.99
MAs MA(5) :  107.4 MA(20) :  104.59
MA(100) :  103.29 MA(250) :  109.73
MACD MACD :  0.1 Signal :  -0.2
%K %D K(14,3) :  57.5 D(3) :  75.3
RSI RSI(14): 45.7
52-week High :  137.08 Low :  79.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RVTY ] has closed above bottom band by 39.4%. Bollinger Bands are 1.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 108.19 - 108.73 108.73 - 109.18
Low: 102.12 - 102.68 102.68 - 103.15
Close: 102.67 - 103.55 103.55 - 104.27
Company Description

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Headline News

Sat, 13 Apr 2024
Allworth Financial LP Acquires Shares of 1060 Revvity, Inc. (NYSE:RVTY) - Defense World

Fri, 12 Apr 2024
Sequoia Financial Advisors LLC Invests $2.71 Million in Revvity, Inc. (NYSE:RVTY) - MarketBeat

Thu, 11 Apr 2024
Asset Management One Co. Ltd. Acquires New Position in Revvity, Inc. (NYSE:RVTY) - Defense World

Wed, 10 Apr 2024
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Wed, 10 Apr 2024
Revvity (RVTY) Stock Jumps 4.1%: Will It Continue to Soar? - Yahoo Finance

Wed, 10 Apr 2024
CENTRAL TRUST Co Makes New $27000 Investment in Revvity, Inc. (NYSE:RVTY) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 124 (M)
Shares Float 112 (M)
Held by Insiders 0.2 (%)
Held by Institutions 88 (%)
Shares Short 3,170 (K)
Shares Short P.Month 3,880 (K)
Stock Financials
EPS 1.44
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 63.77
Profit Margin 25.2 %
Operating Margin 12.4 %
Return on Assets (ttm) 1.7 %
Return on Equity (ttm) 2.3 %
Qtrly Rev. Growth -6.1 %
Gross Profit (p.s.) 0
Sales Per Share 22.26
EBITDA (p.s.) 6.58
Qtrly Earnings Growth -37.3 %
Operating Cash Flow 91 (M)
Levered Free Cash Flow 1,670 (M)
Stock Valuations
PE Ratio 71.86
PEG Ratio 2.5
Price to Book value 1.62
Price to Sales 4.64
Price to Cash Flow 140.06
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android